- Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
- Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
- Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
- Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
- Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
More ▼
Key statistics
On Thursday, Apellis Pharmaceuticals Inc (APLS:NSQ) closed at 39.68, 100.10% above the 52 week low of 19.83 set on Aug 07, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 43.02 |
---|---|
High | 43.13 |
Low | 39.23 |
Bid | 39.70 |
Offer | 40.98 |
Previous close | 39.68 |
Average volume | 1.29m |
---|---|
Shares outstanding | 121.37m |
Free float | 103.98m |
P/E (TTM) | -- |
Market cap | 4.82bn USD |
EPS (TTM) | -3.46 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼